Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drugstore and pharmacy benefits giant CVS Caremark (NYSE: CVS) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at CVS Caremark's business and see what CAPS investors are saying about the stock right now.

CVS Caremark facts

Headquarters (founded) Woonsocket, R.I. (1892)
Market Cap $56.9 billion
Industry Drug retail
Trailing-12-Month Revenue $116.5 billion
Management CEO Larry Merlo (since 2011)
CFO David Denton (since 2010)
Return on Equity (average, past 3 years) 9.7%
Cash/Debt $1.8 billion / $9.4 billion
Dividend Yield 1.4%
Competitors Rite-Aid
Walgreen
Wal-Mart Stores

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 1,732 members who have rated CVS Caremark believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, EVplusEV, succinctly summed up the CVS Caremark bull case for our community:

When Walgreen got into a dispute with [Express Scripts], CVS picked up prescription share. That has been resolved but look for CVS to keep near 50% of those customers. The stock is cheap relative to earnings, good balance sheet, and they provided positive guidance. Looking for [$50 per share] out of this one.  

If you want market-topping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, CVS Caremark may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.